Lazard Capital Upgrades Medtronic to Buy (MDT)
Medtronic (NYSE: MDT) was upgraded by equities researchers at Lazard Capital from a “neutral” rating to a “buy” rating in a report issued on Monday.
Shares of Medtronic opened at 38.37 on Monday. Medtronic has a 52 week low of $30.18 and a 52 week high of $43.33. The company has a market cap of $39.927 billion and a P/E ratio of 12.02.
The company last announced its quarterly results on Tuesday, February 21st. It reported $0.88 earnings per share (EPS) for the previous quarter, beating the Thomson Reuters consensus estimate of $0.84 EPS by $0.04. The company’s quarterly revenue was down 1.1% on a year-over-year basis. On average, analysts predict that Medtronic will post $0.87 earnings per share next quarter.
A number of other analysts have also recently weighed in on MDT. Analysts at Bank of America (NYSE: BAC) raised their price target on shares of Medtronic from $42.00 to $45.00 in a research note to investors on Thursday, April 5th. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Medtronic in a research note to investors on Wednesday, March 28th. They now have a $42.00 price target on the stock. Finally, analysts at Oppenheimer (NYSE: OPY) cut their EPS estimates on shares of Medtronic in a research note on Tuesday. They now have an “outperform” rating on the stock.
Medtronic, Inc. (Medtronic) is a medical technology company. The Company is engaged in research, design, manufacture and sale of products to alleviate pain, restore health and extend life.